New York, April 03, 2024 - PRISM MarketView - IceCure Medical Ltd. (Nasdaq: ICCM) has filed a 510(k) submission with the FDA for clearance of its next-generation single probe cryoablation system, the XSense™ System and cryoprobes.
“As our ProSense® single probe cryoablation system builds market traction globally, we continue to develop our technology pipeline with innovative single and multi-probe systems.”
IceCure’s CEO, Eyal Shamir
“We believe IceCure is the technological, clinical and market leader in liquid nitrogen-based cryoablation technologies that can have a significant beneficial impact on global healthcare systems by offering safe, effective, patient-friendly and cost-efficient alternatives to more invasive surgical procedures.”
IceCure’s CEO, Eyal Shamir
The filing contains a request for clearance for the XSense System in indications including general minimally invasive cryoablation applications for the kidney, liver, fibroadenomas and neurology. IceCure’s ProSense® system has already received FDA clearance for these indications.
IceCure’s ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them in a fast and convenient office-based procedure.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
IceCure Medical Ltd. (Nasdaq: ICCM) is featured on PRISM Emerging MedDevices Index
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)